At just 32 years old, Christina Hornyak’s life took an unexpected turn when she was diagnosed with heart failure, three years after conquering a rare and aggressive form of breast cancer. Her story uncovers a critical yet often overlooked connection between cancer treatments and cardiovascular health.
Early Battle with Cancer
Hornyak’s journey began in 2021 at the age of 29 when she received a diagnosis of triple-negative breast cancer, a particularly aggressive type of the disease. The news was devastating and unexpected. Living an active lifestyle, she had never anticipated facing such a formidable health challenge so early in life.
“I’ve never smoked. I’ve never been a big drinker. I live an active lifestyle,” Hornyak reflected. The diagnosis led her to undergo an intense treatment regimen, including 16 rounds of chemotherapy. While celebrating her victory over cancer, she remained unaware of the potential long-term risks associated with her treatment.
The Hidden Risks of Chemotherapy
Hornyak’s doctors recommended an anthracycline chemotherapy, a powerful treatment known for its effectiveness against aggressive cancers. However, this therapy carries a significant risk of heart damage. “I learned that one of the chemotherapies I was going to receive had the potential to be difficult on the heart,” she explained.
Despite the risks, Hornyak embraced the treatment, believing it was a necessary step toward her recovery. Little did she know that the very drugs saving her life could also jeopardize her heart health in the future.
Struggling with Symptoms
After several years of being cancer-free, Hornyak noticed troubling symptoms. “I started getting very, very, very tired,” she said, emphasizing the extreme fatigue that accompanied even the simplest tasks. This overwhelming exhaustion led her to seek medical attention, culminating in a shocking revelation about her heart function.
“My cardiologist called me and said that my ejection fraction had reduced down to 30%,” Hornyak recalled, struck by the gravity of her situation. An ejection fraction (EF) below 50% indicates compromised heart function, raising significant health concerns.
The Cardio-Oncology Connection
Following her diagnosis, Hornyak was referred to Dr. Zackary Tushak, director of Sentara’s Cardio-Oncology Program. This specialized program focuses on the intersection of cancer treatment and heart health, highlighting the importance of monitoring cardiovascular function in oncology patients.
“Cardio oncology is the intersection of cancer, its treatment, and how it affects the heart,” Dr. Tushak noted. He emphasized that while advancements in oncology have improved patient outcomes, there remain risks, particularly for young patients like Hornyak.
Monitoring Heart Health
Dr. Tushak explained the three-phase approach used to monitor patients at risk for heart complications due to cancer treatments. The first phase involves assessing pre-existing cardiovascular conditions, followed by the treatment phase, where patients receive active monitoring during chemotherapy. Hornyak is currently in the survivorship phase, working closely with her medical team to ensure her heart health remains stable.
“Through the collaboration between me, Christina, and her other cardiologists, we’ve now gotten her function back up to normal,” Dr. Tushak stated. This collaborative effort has significantly improved Hornyak’s quality of life.
Returning to Normalcy
With her heart function stabilized, Hornyak has resumed a more typical lifestyle. “I was able to go to Disney last year and celebrate my niece’s 16th birthday,” she shared. Despite experiencing occasional setbacks, she remains optimistic and grateful for her journey.
“Sometimes I have bad days, but I also have a lot of really great days,” Hornyak expressed. Her resilience serves as an inspiration to others facing similar challenges.
Embracing the Journey
Hornyak encourages others to face their health challenges without fear. “In my case, the benefit outweighed the risk,” she asserted. She highlights the importance of monitoring and education throughout the treatment process, emphasizing that patients should not shy away from necessary therapies due to potential side effects.
During her journey, Hornyak discovered a genetic mutation that predisposed her to heart failure. This revelation underscores the importance of genetic testing, which can identify mutations that increase the risk of various health conditions.
Conclusion
Christina Hornyak’s story is a powerful reminder of the complexities surrounding cancer treatment and heart health. Her experience emphasizes the need for vigilant monitoring and comprehensive care for survivors. As she continues to navigate her health journey, Hornyak exemplifies resilience, hope, and the importance of informed decision-making in healthcare.
- Cancer treatments can have long-term effects on heart health.
- Regular monitoring is crucial for patients receiving chemotherapy.
- Genetic testing can provide valuable insights into individual health risks.
- Collaboration between oncologists and cardiologists can enhance patient care.
- Resilience and a positive mindset can greatly impact recovery and quality of life.
Read more → www.wtkr.com